Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 - 37. (Canceled)

38. (Currently Amended) An *in vitro* method of functionally determining ~~at physiological conditions~~ deficiencies in ~~the~~a lectin pathway of ~~the~~ complement ~~system, employing~~ in a sample of ~~mammalian~~ blood, serum, or plasma~~, or another body fluid~~ obtained from a mammal, the method comprising the steps of

(a) adding ~~an~~a C1 complex inhibitor to the sample to inhibit a classical pathway of complement, the C1 complex inhibitor comprising:~~selected from the group consisting of~~

an inhibitory C1q-binding protein[[s]] selected from the group consisting of C1 inhibitor, CRT, C1Qr, E.coli C1g binding protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, and surfactant protein A,

~~peptides~~a peptide inhibitor of C1q, C1r or C1s selected from the group consisting of TDGDKAFVDFLSDEIKEE (SEQ ID NO. 1), KDIRCKDD (SEQ ID NO. 2), AEAKAKA (SEQ ID NO. 3), VQVHNAKTKPR (SEQ ID NO. 4), WY, CEGPFGPRHDLTFCW (SEQ ID NO. 5), ~~and~~ LEQGENVFLQATLL (SEQ ID NO. 6), CRWDGSWGEVRC (SEQ ID NO. 7), CMWVRMWGDVNC (SEQ ID NO. 8), CFWAGKFGLGTC (SEQ ID NO. 9), CKDRWVVEERCC (SEQ ID NO. 10), and CWNRFKKMDRC (SEQ ID NO. 11), or

an immunoglobulin[[s]] that binds ~~against~~ C1q, C1r or C1s;

(b) diluting the sample with a buffered aqueous media having physiological pH and physiological ion strength to inhibit the activation of ~~the~~ an alternative pathway of complement;

(c) adding a ~~MBL (~~mannan-binding lectin~~)~~ (MBL) or ficolin binding carbohydrate to activate ~~activating~~ the lectin pathway of complement in the sample;

(d) adding ~~ana~~ first antibody ~~against the~~ to the sample that specifically binds ~~autologous~~ C5b-9 complex to detect formation of C5b-9 complex in the sample, and

(e) determining ~~the~~ activation of the lectin pathway in the sample at the physiological ~~condition~~conditions by measuring the ~~autologous~~ amount of C5b-9 complex detected in the sample.

39. (Canceled)

40. (Canceled)

41. (Currently Amended) The method according to claim 38, wherein ~~the~~said inhibitor in step (a) is an immunoglobulin selected from the group consisting of polyclonal and monoclonal antibodies.

42. (Currently Amended) The method according to claim 38, wherein ~~the~~said carbohydrate in step (c) is selected from the group consisting of mannose, fucose, or mannan ~~such as glucomannan and galactomannan, synthetic carbohydrate and microbial polysaccharide~~.

43. (Currently Amended) The method according to claim 38, wherein ~~the~~said first antibody in step (d) is a polyclonal or a monoclonal antibody.

44. (Currently Amended) The method according to claim [[43]]38, wherein the step in (d) comprises adding a second antibody that binds ~~the~~said first antibody, wherein said second antibody is a labeled antibody.

45. (Currently Amended) The method according to claim 43, wherein ~~the~~said first antibody is a labeled antibody.

46. (Withdrawn - Currently Amended) A kit for functionally determining deficiencies in a lectin pathway of complement in a body fluid from a mammal, the kit comprising:

(a) an inert carrier and a mannan-binding lectin (MBL) or ficolin binding carbohydrate for activating the lectin pathway of complement;

(b) a diluent comprising a C1 complex inhibitor for inhibiting a classical pathway of complement, the C1 complex inhibitor comprising: ~~selected from the group consisting of~~

an inhibitory C1q-binding protein[[s]] selected from the group consisting of C1 inhibitor, CRT, C1Qr, E.coli C1g binding protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, and surfactant protein A,

~~peptides~~a peptide inhibitor of C1q, C1r or C1s selected from the group consisting of TDGDKAFVDFLSDEIKEE (SEQ ID NO. 1), KDIRCKDD (SEQ ID NO. 2), AEAKAKA (SEQ ID NO. 3), VQVHNAKTKPR (SEQ ID NO. 4), WY, CEGPFGPRHDLTFCW (SEQ ID NO. 5), ~~and~~ LEQGENVFLQATLL (SEQ ID NO. 6), CRWDGSWGEVRC (SEQ ID NO. 7), CMWVRMWGDVNC (SEQ ID NO. 8), CFWAGKFGLGTC (SEQ ID NO. 9), CKDRWVVEERCC (SEQ ID NO. 10), and CWNRFKKMDRC (SEQ ID NO. 11), or

an immunoglobulin[[s]] that binds ~~against~~ C1q, C1r or C1s; and

(c) a first antibody that specifically binds a ~~against the autologous~~ C5b-9 complex~~, for functionally determining in a body fluid from a mammal deficiencies in the lectin pathway of the complement system~~.

47. (Withdrawn – Currently Amended) The kit according to claim 46, wherein the carbohydrate in (a) is selected from the group consisting of mannose, fucose, or mannan ~~such as glucomannan and galactormannan, synthetic carbohydrate and microbial polysaccharide~~.

48. (Canceled)

49. (Canceled)

50. (Withdrawn – Currently Amended) The kit according to claim 46, wherein the inhibitor in (b) is an immunoglobulin selected from the group consisting of polyclonal and monoclonal antibodies.

51. (Withdrawn) The kit according to claim 46, wherein the first antibody in (c) is a polyclonal or monoclonal antibody.

52. (Withdrawn) The kit according to claim 47, wherein the carbohydrate in (a) is coated on the inert carrier.

53. (Withdrawn) The kit according to claim 51, wherein the first antibody in (c) is a labeled antibody.

54. (Withdrawn – Currently Amended) The kit according to claim [[51]]46, wherein the kit further comprises a labeled second antibody (d) ~~against~~that binds the first antibody in (c).

55. (Withdrawn) The kit according to claim 53, wherein the kit further comprises an enzyme substrate (e).

56. (Withdrawn) The kit according to claim~~s~~ 46, wherein the kit further comprises a washing solution (f).

57. (Withdrawn) The kit according to claim 46, wherein the kit further comprises a normal body liquid from a mammal (g).

58. (Withdrawn) The kit according to claim 57, wherein the normal body liquid (g) is a human serum.

59. (Withdrawn) The kit according to claim 46, wherein the kit further comprises an inactivated normal body liquid from a mammal (h).

60. (Withdrawn) The kit according to claim 59, wherein the inactivated normal body liquid (h) is heat inactivated human serum.

61. (New) The method according to claim 42, wherein said mannan is glucomannan or galactomannan.

62. (New) The kit according to claim 47, wherein said mannan is glucomannan or galactomannan.